Dr. Alice Cohen had led the comprehensive cancer and blood disorders center at Newark Beth Israel Medical Center that was founded by her father since 1998. Now, a new director has taken on the role, as Cohen transitions to section chief of hematology, where she will continue to provide leadership for the sector, and the center’s sickle cell program, which she developed.

On March 1, Newark Beth Israel Medical Center, a RWJBarnabas Health facility and clinical component of Rutgers Cancer Institute of New Jersey, announced Dr. Sari Jacoby as the new medical director of the Frederick B. Cohen, MD Comprehensive Cancer and Blood Disorders Center.

“We are extremely grateful to Dr. Cohen for her leadership and dedication to her patients and the cancer program at NBI and look forward to working closely with Dr. Jacoby to continue to enhance cancer services, bringing the most advanced treatment options such as clinical trials to patients in the Greater Newark area,” said RWJBarnabas Health System Vice President for Strategy and Operations, Oncology Services Susan Solometo.

Jacoby joined NBI from Long Island Jewish Medical Center, where she completed her internship, residency and fellowship, in 2011. Her clinical interests include gastrointestinal malignancies and complex blood disorders such as hemophilia and sickle cell disease.

According to NBI, and due in large part to the partnership with Rutgers Cancer Institute of New Jersey, The Frederick B. Cohen, MD Comprehensive Cancer and Blood Disorders Center offers advanced treatment options, including clinical trials, novel therapies, precision medicine and immunotherapy

Rutgers Cancer Institute of New Jersey is the state’s only National Cancer Institute-designated Comprehensive Cancer Center.

“It is a privilege to work with a multidisciplinary team of nationally recognized experts in hematology, surgical, medical and radiation oncology, as well as patient navigators, genetic counselors, social workers, dietitians and lymphedema specialists. I look forward to leading this team as we continue to push the envelope and deliver the latest advances in cancer care to our patients,” Jacoby said in a prepared statement.